$ 905.92
Details
The Human ErbB2 (HER2) ELISA quantitates Hu HER2 in human serum, plasma, or cell culture medium. The assay will exclusively recognize both natural and recombinant Hu HER2. Principle of the method The Human HER2 solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.ErbB2 (Her2/neu) is a 185 kDa transmembrane receptor tyrosine kinase from the EGFR (epidermal growth factor receptor) family that regulates biological responses such as cell growth, differentiation, and tissue development. ErbB2 has no ligand binding domain of its own and cannot bind growth factors. However, ErbB2 does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signaling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Autophosphorylation of tyrosine 1139 on ErbB2 allows binding of Grb2 and the Src SH2 domain, which allows activation of the Ras, Raf, ERK1/2 and JAK/STAT signaling pathways, respectively. Alternative splicing of ErbB2 results in several transcript variants, some encoding different isoforms and others that have not been fully characterized. In humans, the gene encoding ERBB2 is present on chromosome 17. Amplification and/or overexpression of the ErbB2 gene has been reported in ovarian tumors, breast, lung and skin cancer.
